Professor of Medicine, University Tex Houston
Oncology
Dr. Christopher J. Logothetis, MD
|
|
Give Review
Christopher Logothetis is an expert in the field of Oncology. He received awards:"America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer" and "Super Doctor". Doctor Christopher J. Logothetis, MD is a published doctor as well. He has 100 publications published. The latest was: Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. He accepts Medicare.
Publications
- Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
- Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
- Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer.
- Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.
- Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate Cancer.
- Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR-2 as Targets for Growth Inhibition of Prostate Cancer.
- Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate Cancer and their receptors.
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate Cancer (COU-AA-302): final o...
- Discovery and horizontal follow-up of an autoantibody signature in human prostate Cancer.
- The Relationship Between Illness Uncertainty, Anxiety, Fear of Progression, and Quality of Life in Men With Favorable Risk Prostate Cancer Undergoing Active Surveillance.
- Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiratero...
- Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results.
- Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of Cancer and stromal cells within the tumor microenviron...
- The Prostate Cancer Susceptibility Variant rs2735839 Near KLK3 Gene Is Associated with Aggressive Prostate Cancer and Can Stratify Gleason Score 7 Patients.
- Prostate Cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.
- Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study.
- Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate Cancer.
- Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate Cancer clinic.
- Aggressive variants of castration-resistant prostate Cancer.
- Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer.
- Prostate Cancer bone metastases: not so systemic after all.
- PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in Cancer.
- Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate Cancer (READY): a randomised, double-blind phase 3 trial.
- Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate Cancer: patient-reported outcome re...
- Molecular classification of prostate Cancer progression: foundation for marker-driven treatment of prostate Cancer.
- Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression.
- Re: intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
- Prevalence of Pain and Analgesic Use in Men With Metastatic Prostate Cancer Using a Patient-Reported Outcome Measure.
- Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer.
- Treatment of Castrate-Resistant Prostate Cancer.
- Ligand-independent activation of MET through IGF-1/IGF-1R signaling.
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial.
- Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate Cancer by decreasing activated survival pathways.
- Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate Cancer.
- Targeting Constitutively Activated ?1 Integrin inhibits Prostate Cancer Metastasis.
- Abiraterone in metastatic prostate Cancer without previous chemotherapy.
- Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-re...
- Building a statistical model for predicting Cancer genes.
- PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation The...
- Effect of Paget's disease of bone (osteitis deformans) on the progression of prostate Cancer bone metastasis.
- Integrated Hedgehog signaling is induced following castration in human and murine prostate Cancers.
- In silico functional profiling of individual prostate Cancer tumors: many genes, few functions.
- Beyond comparing means: the usefulness of analyzing interindividual variation in gene expression for identifying genes associated with Cancer development.
- Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate Cancer xenograft MDA PCa 118b.
- Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone.
- Modeling Lethal Prostate Cancer Variant with Small Cell Carcinoma Features.
- Personalized oncology through integrative high-throughput sequencing: a pilot study.
- Treatment of prostate Cancer metastases: more than semantics.
- Vascular ligand-receptor mapping by direct combinatorial selection in Cancer patients.
- Understanding the lethal variant of prostate Cancer: power of examining extremes.
- The role of HGF/c-Met signaling in prostate Cancer progression and c-Met inhibitors in clinical trials.
- Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer.
- Dasatinib combined with docetaxel for castration-resistant prostate Cancer: Results from a phase 1-2 study.
- Aberrant expression of katanin p60 in prostate Cancer bone metastasis.
- Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate Cancer displaying bone flare discordant with serologic response.
- Neuroendocrine prostate Cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene e...
- Persistent, Biologically Meaningful Prostate Cancer After 1 Year of Androgen Ablation and Docetaxel Treatment.
- Androgen regulation of 5?-reductase isoenzymes in prostate Cancer: implications for prostate Cancer prevention.
- Adipose tissue-derived stem Cells promote prostate tumor growth.
- Cadherin-11 increases migration and invasion of prostate Cancer cells and enhances their interaction with osteoblasts.
- Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
- Multimodality therapy: bone-targeted radioisotope therapy of prostate Cancer.
- A new therapy paradigm for prostate Cancer founded on clinical observations.
- Housekeeping genes in Prostate tumorigenesis.
- Dasatinib inhibits both osteoclast activation and prostate Cancer PC-3-cell-induced osteoclast formation.
- Informative clinical investigation: a demanding taskmaster.
- Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate Cancer.
- NY-ESO-1 DNA vaccine induces T-Cell responses that are suppressed by regulatory T Cells.
- Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate Cancer.
- Inhibition of RNA-dependent protein kinase (PKR) leads to Cancer cell death and increases chemosensitivity.
- GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate Cancer as an example.
- Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate Cancer.
- Androgen receptor-negative human prostate Cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms.
- Cadherin-11 promotes the metastasis of prostate Cancer cells to bone.
- High-grade prostate Cancer and the prostate Cancer prevention trial.
- Soluble ErbB3 levels in bone marrow and plasma of men with prostate Cancer.
- Chemotherapy for advanced prostate Cancer: 25 years later.
- Understanding the biology of bone metastases: key to the effective treatment of prostate Cancer.
- Strategy for the application of therapy in prostate Cancer.
- Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate Cancer therapies.
- Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate Cancer with bone metastases.
- A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate Cancer cells.
- Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate Cancer.
- Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder Cancer.
- Review of late complications of treatment and late relapse in testicular Cancer.
- Identification of Cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression.
- Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate Cancer.
- Pathogenesis and treatment of prostate Cancer bone metastases: targeting the lethal phenotype.
- Therapy tolerance in selected patients with androgen-independent prostate Cancer following strontium-89 combined with chemotherapy.
- Obesity, weight gain, and risk of biochemical failure among prostate Cancer patients following prostatectomy.
- Suppression of prostate tumor cell growth by stromal cell prostaGlandin D synthase-derived products.
- Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia.
- Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate Cells.
- Clinical and biomarker correlates of androgen-independent, locally aggressive prostate Cancer with limited metastatic potential.
- Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ Cell tumors.
- Androgen receptor polymorphisms and risk of biochemical failure among Prostatectomy patients.
- Bortezomib as a potential treatment for prostate Cancer.
- Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate Cancer.
- Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity.
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Blue Choice
- Cigna HMO
- Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- Golden Rule
- GEHA
- HealthSmart
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- Super Doctor
Education
-
University of Texas Health Science Center -
University of Texas MD Anderson Cancer Center -
University of Athens
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1477654721 | |
| NPPES Provider LastName | LOGOTHETIS | |
| NPPES Provider FirstName | CHRISTOPHER | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 326.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 12.0 | |
| Percent Opioid Claims | 3.68 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1477654721 |
| Last Name Of The Provider | LOGOTHETIS |
| First Name Of The Provider | CHRISTOPHER |
| View All |
Similar Doctors
|
|
Dr. Nikesh Jasani, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Ronald S. Walters, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gerald S. Falchook, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Issa F. Khouri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katherine M. Pisters, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria A. Zarzour, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Joan M. Bull, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott M. Lippman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Abenaa M. Brewster, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aihua E. Yen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stacy L. Moulder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pierre Saintigny, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Faye M. Johnson, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Philip A. Salem, MD
This Doctor is OpenDoctor Recommended.
|